Quantcast
Last updated on April 25, 2014 at 5:24 EDT

Latest Silence Therapeutics plc Stories

2011-09-21 01:00:00

LONDON, September 21, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Tony Sedgwick PhD, FRCPath as Chief Business Officer with immediate effect. Dr Sedgwick will be based in Silence's London office and lead the growing Business Development team within Silence. Tony Sedgwick is an experienced biotechnology and...

2011-09-21 01:00:00

LONDON, September 21, 2011 /PRNewswire/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011. Highlights - New German-based CEO appointed - Business development operations strengthened, including the appointment of a Chief Business Officer, highlighting an increased commercial focus...

2011-09-20 01:00:00

LONDON, September 20, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Thomas Christely as Chief Executive Officer with immediate effect. He will be based at Silence's facility in Berlin. Thomas Christely (aged 51) brings more than 20 years experience in corporate and business development and finance. He was instrumental in...

2011-09-16 01:00:00

LONDON, September 16, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office. The issued patent covers certain methods for screening a therapeutic agent for the treatment and/or prevention of any disease that involves elevated activity within the PI3-kinase pathway. More...

2011-09-12 01:00:00

LONDON and NIJMEGEN and UTRECHT, The Netherlands, September 12, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading global RNA interference (RNAi [http://www.silence-therapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, and InteRNA Technologies B.V. ("InteRNA"), a biopharmaceutical company developing pathway targeted microRNA ("miRNA")-based therapeutics for cancer, today announce that they have entered into an agreement to...

2011-09-08 04:49:00

LONDON, September 8, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announced that Max Herrmann, chief financial officer and acting chief executive officer, and Thomas Christely, chief operating officer, will present corporate updates at two upcoming industry and financial conferences. Their presentations will include an update on corporate and clinical progress,...

2011-08-03 06:00:00

LONDON, August 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office has issued the Company a notice of allowance on a patent application directed to the fundamental technology involved in AtuPLEX(TM), one of Silence's proprietary small interfering RNA (siRNA) delivery systems. The allowable subject matter is directed to...

2011-06-06 08:00:00

LONDON, June 6, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces positive updated data from its ongoing Phase I study of Atu027, one of the most clinically advanced RNAi therapeutics in the area of oncology, in patients with advanced solid tumors. Study results show that nine of the 24 patients treated with Atu027 to date achieved stable disease after repeated treatment...

2011-05-18 17:05:00

LONDON, May 18, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology ("ASCO") Annual Meeting on 06 June 2011. Top-line data includes results for 21 patients who received the study's first seven escalating...

2011-05-03 01:00:00

LONDON, May 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office. The issued patent covers aspects of Silence's platform of novel, short interfering RNA (siRNA) molecules containing 2'-O-Methyl structures known as AtuRNAi. Silence's AtuRNAi molecules offer important advantages over conventional siRNA molecules including...